株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Alba Therapeutics Corporation.:製品パイプライン分析

Alba Therapeutics Corporation - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 251741
出版日 ページ情報 英文 28 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
Alba Therapeutics Corporation.:製品パイプライン分析 Alba Therapeutics Corporation - Product Pipeline Review - 2015
出版日: 2015年05月13日 ページ情報: 英文 28 Pages
概要

Alba Therapeutics Corporationは、主に自己免疫疾患及び炎症性疾患の治療薬を発見し、開発・製品化しているバイオ製薬会社です。同社の技術プラットフォームは、細胞間の分子の流れを調えることで自己免疫疾患および炎症性疾患を治療するのに活用されています。また、胃腸、代謝、肺、腎臓などの疾患といった、多様に分類される免疫ベースの疾患に対して治療薬を提供しています。

当レポートでは、Alba Therapeutics Corporationにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Alba Therapeutics Corporationの基本情報

  • Alba Therapeutics Corporationの概要
  • 主要情報
  • 企業情報

Alba Therapeutics Corporation:R&Dの概要

  • 主な治療範囲

Alba Therapeutics Corporation:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Alba Therapeutics Corporation:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Alba Therapeutics Corporation:薬剤プロファイル

  • larazotide acetate
  • AT-1004
  • AT-1006
  • AT-1005
  • Drug 1 to Inhibit Permeability for Autoimmune Disorders and Inflammation
  • Drug 2 to Inhibit Permeability for Autoimmune Disorders and Inflammation

Alba Therapeutics Corporation:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Alba Therapeutics Corporation:最近のパイプライン動向

Alba Therapeutics Corporation:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07069CDB

Summary

Global Markets Direct's, 'Alba Therapeutics Corporation - Product Pipeline Review - 2015', provides an overview of the Alba Therapeutics Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Alba Therapeutics Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Alba Therapeutics Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Alba Therapeutics Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Alba Therapeutics Corporation's pipeline products

Reasons to buy

  • Evaluate Alba Therapeutics Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Alba Therapeutics Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Alba Therapeutics Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Alba Therapeutics Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Alba Therapeutics Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Alba Therapeutics Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Alba Therapeutics Corporation Snapshot
    • Alba Therapeutics Corporation Overview
    • Key Information
    • Key Facts
  • Alba Therapeutics Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Alba Therapeutics Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Alba Therapeutics Corporation - Pipeline Products Glance
    • Alba Therapeutics Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Alba Therapeutics Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Alba Therapeutics Corporation - Drug Profiles
    • larazotide acetate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AT-1004
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AT-1006
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AT-1005
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Induce Permeability for Autoimmune Disorders and Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit Permeability for Autoimmune Disorders and Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Alba Therapeutics Corporation - Pipeline Analysis
    • Alba Therapeutics Corporation - Pipeline Products by Target
    • Alba Therapeutics Corporation - Pipeline Products by Route of Administration
    • Alba Therapeutics Corporation - Pipeline Products by Molecule Type
    • Alba Therapeutics Corporation - Pipeline Products by Mechanism of Action
  • Alba Therapeutics Corporation - Recent Pipeline Updates
  • Alba Therapeutics Corporation - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Alba Therapeutics Corporation, Key Information
  • Alba Therapeutics Corporation, Key Facts
  • Alba Therapeutics Corporation - Pipeline by Indication, 2015
  • Alba Therapeutics Corporation - Pipeline by Stage of Development, 2015
  • Alba Therapeutics Corporation - Monotherapy Products in Pipeline, 2015
  • Alba Therapeutics Corporation - Phase II, 2015
  • Alba Therapeutics Corporation - Phase I, 2015
  • Alba Therapeutics Corporation - Preclinical, 2015
  • Alba Therapeutics Corporation - Discovery, 2015
  • Alba Therapeutics Corporation - Pipeline by Target, 2015
  • Alba Therapeutics Corporation - Pipeline by Route of Administration, 2015
  • Alba Therapeutics Corporation - Pipeline by Molecule Type, 2015
  • Alba Therapeutics Corporation - Pipeline Products by Mechanism of Action, 2015
  • Alba Therapeutics Corporation - Recent Pipeline Updates, 2015

List of Figures

  • Alba Therapeutics Corporation - Pipeline by Top 10 Indication, 2015
  • Alba Therapeutics Corporation - Pipeline by Stage of Development, 2015
  • Alba Therapeutics Corporation - Monotherapy Products in Pipeline, 2015
  • Alba Therapeutics Corporation - Pipeline by Top 10 Target, 2015
  • Alba Therapeutics Corporation - Pipeline by Top 10 Route of Administration, 2015
  • Alba Therapeutics Corporation - Pipeline by Top 10 Molecule Type, 2015
  • Alba Therapeutics Corporation - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top